Editorial
doi: 10.1634/theoncologist.2009-0306.
Epub 2010 Jan 19.
Histology matters: individualizing treatment in non-small cell lung cancer
- PMID: 20086166
- PMCID: PMC3227884
- DOI: 10.1634/theoncologist.2009-0306
Item in Clipboard
Editorial
Histology matters: individualizing treatment in non-small cell lung cancer
Oncologist.
2010.
Abstract
This editorial discusses the role of histology in non-small cell lung cancer treatment.
Conflict of interest statement
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the author or independent peer reviewers.
Similar articles
-
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.Clin Adv Hematol Oncol. 2014 Jan;12(1 Suppl 1):13. Clin Adv Hematol Oncol. 2014. PMID: 24852397 Clinical Trial. No abstract available.
-
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.J Clin Oncol. 2010 Nov 1;28(31):4747-54. doi: 10.1200/JCO.2009.27.9356. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921467 Free PMC article. Clinical Trial.
-
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921461 Review.
-
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444843 Clinical Trial.
-
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].Magy Onkol. 2010 Jun;54(2):137-43. doi: 10.1556/MOnkol.54.2010.2.8. Magy Onkol. 2010. PMID: 20576590 Review. Hungarian.
Cited by
-
Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.J Clin Oncol. 2012 Apr 1;30(10):1129-36. doi: 10.1200/JCO.2011.37.4231. Epub 2012 Feb 21. J Clin Oncol. 2012. PMID: 22355056 Free PMC article.
-
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).Oncologist. 2010;15(12):1352-8. doi: 10.1634/theoncologist.2010-0224. Epub 2010 Dec 10. Oncologist. 2010. PMID: 21148615 Free PMC article. Clinical Trial.
-
Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.J Exp Clin Cancer Res. 2010 Sep 15;29(1):125. doi: 10.1186/1756-9966-29-125. J Exp Clin Cancer Res. 2010. PMID: 20843314 Free PMC article.
-
Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration.JAMA Netw Open. 2022 Apr 1;5(4):e227958. doi: 10.1001/jamanetworkopen.2022.7958. JAMA Netw Open. 2022. PMID: 35438753 Free PMC article.
-
One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.Clin Cancer Res. 2011 Feb 15;17(4):638-9. doi: 10.1158/1078-0432.CCR-10-3081. Epub 2010 Dec 16. Clin Cancer Res. 2011. PMID: 21163872 Free PMC article.
References
-
- Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550. - PubMed
-
- Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–1440. - PubMed
-
- Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009;27:3284–3289. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
